Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKesson
Johnson and Johnson
Baxter
Express Scripts

Last Updated: October 6, 2022

Peramivir - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for peramivir and what is the scope of patent protection?

Peramivir is the generic ingredient in one branded drug marketed by Biocryst and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Peramivir has sixty-seven patent family members in twenty-eight countries.

There is one drug master file entry for peramivir.

Summary for peramivir
International Patents:67
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 1
Raw Ingredient (Bulk) Api Vendors: 79
Clinical Trials: 15
Patent Applications: 3,147
What excipients (inactive ingredients) are in peramivir?peramivir excipients list
DailyMed Link:peramivir at DailyMed
Recent Clinical Trials for peramivir

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hoffmann-La RochePhase 3
Johns Hopkins UniversityPhase 4
Department of Health and Human ServicesPhase 4

See all peramivir clinical trials

US Patents and Regulatory Information for peramivir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for peramivir

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Biocryst Alpivab peramivir EMEA/H/C/004299
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
Withdrawn no no no 2018-04-13
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for peramivir

Country Patent Number Title Estimated Expiration
Spain 2324746 See Plans and Pricing
Mexico 2008010394 TRATAMIENTOS ANTIVIRALES INTRAVENOSOS. (INTRAVENOUS ANTIVIRAL TREATMENTS.) See Plans and Pricing
Hong Kong 1212250 抗病毒化合物、包含該化合物的劑型及其用途 (ANTIVIRAL COMPOUNDS, UNIT DOSAGE FORM COMPRISING SAID COMPOUNDS AND USE THEREOF) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Baxter
Merck
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.